

**Investor Call – 8:00am AWST Wednesday 12 August 2020**

**Announcement**

PYC Therapeutics (ASX: PYC) ('PYC') will host an investor call for shareholders on Wednesday 12 August 2020 at 8am AWST (10am AEST). The management team of PYC will address questions on the progress of the lead drug, VP-001, as PYC continues to push the drug towards clinical development, as well as the company's plans to scale the retinal drug pipeline over the next 12 months.

Questions can be submitted at [info@pyctx.com](mailto:info@pyctx.com)

Please register at the link below to be assigned dial-in and viewing details:


<https://zoom.us/j/97307359648?pwd=L3JKNmF1QkVoQUU4M2JTVE02cWJMUT09>

*This ASX announcement was approved and authorised for release by the Board of PYC Therapeutics Limited.*

**ENDS** For further information, please contact:

**INVESTORS**  
Kaggen Ausma  
CBO  
[info@pyctx.com](mailto:info@pyctx.com)

**About PYC Therapeutics** - PYC Therapeutics (ASX: PYC) is a drug development company solving a major challenge in the development of a revolutionary new class of drugs – delivering large drugs into cells. Cell Penetrating Peptides (CPPs) can overcome ‘the delivery challenge’ and provide access for a wide range of potent and precise drug ‘cargoes’ to the ‘undruggable genome’ – the highest value drug targets that exist inside cells. PYC Therapeutics is using its CPP platform to develop a pipeline of novel therapies with an initial focus on inherited retinal diseases.



#### Overview

- **High-performing precision medicine** – combines a Cell Penetrating Peptide (CPP) and Antisense Oligonucleotide (ASO) to treat a form of Retinitis Pigmentosa
  - **Pre-clinical efficacy and toxicity validation** – drug proven to treat the disease process in models derived from patient cells and shown to be non-toxic in mouse models
  - **Commercial attractiveness** – US\$1bn+ market with a high unmet need and accessible patients. Human trials beginning in mid-2021 with relatively high probability of success of reaching market in early 2025 given target indication
- 
- **Established development pipeline** – six opportunities being developed with a subset expected to reach the IND-enabling stage-gate by end of 2020
  - **Distinctive capabilities** – Vision Pharma partnership combines PYC’s RNA therapeutic expertise with the Lions Eye Institute’s world leading retinal tissue and clinical expertise
- 
- **Competitively differentiated** – enhanced performance and safety of CPP-ASOs v. other ASO and broader RNA/DNA therapeutics
  - **Ability to scale** – highly efficient process to design and validate RNA therapeutics once targets are identified
  - **Applicable to broad set of tissues** – currently evaluating performance in multiple tissues
- 
- **Proprietary peptide libraries** – diversity of libraries, quality of screening assays, richness of data, and advanced analytics capabilities allow for broad applications
  - **Capabilities** – Internal expertise in precision medicine coupled with partnerships with clinicians. Commercial excellence and global reach through Australian and US offices

#### Forward looking statements

Any forward-looking statements in this ASX announcement have been prepared on the basis of a number of assumptions which may prove incorrect and the current intentions, plans, expectations and beliefs about future events are subject to risks, uncertainties and other factors, many of which are outside the Company’s control. Important factors that could cause actual results to differ materially from assumptions or expectations expressed or implied in this ASX announcement include known and unknown risks. Because actual results could differ materially to assumptions made and the Company’s current intentions, plans, expectations and beliefs about the future, you are urged to view all forward-looking statements contained in this ASX announcement with caution. The Company undertakes no obligation to publicly update any forward-looking statement whether as a result of new information, future events or otherwise.

This ASX announcement should not be relied on as a recommendation or forecast by the Company. Nothing in this ASX announcement should be construed as either an offer to sell or a solicitation of an offer to buy or sell shares in any jurisdiction.

Tel: +61 8 6151 0994

pyctx.com

**PYC Therapeutics**

ACN 098 391 961